Orforglipron (LY-3502970) is a non-peptide glucagon-like peptide-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company.[1][2] It is easier to produce than GLP-1 agonists on the market in 2023 and is expected to be cheaper.[3]

See also

References

  1. ^ Pratt E, Ma X, Liu R, Robins D, Coskun T, Sloop KW, et al. (June 2023). "Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes". Diabetes, Obesity & Metabolism. 25 (9): 2642–2649. doi:10.1111/dom.15150. PMID 37264711. S2CID 259022851.
  2. ^ Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. (June 2023). "Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity". The New England Journal of Medicine. 389 (10): 877–888. doi:10.1056/NEJMoa2302392. PMID 37351564.
  3. ^ Sidik, Saima (2023). "Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective". Nature. 619 (7968): 19. Bibcode:2023Natur.619...19S. doi:10.1038/d41586-023-02092-9. PMID 37369789.